1. Sato, K., Matsuura, Y., Inoue, M., Une, T., Osada, Y., Ogawa, H., Mitsuhashi, S. In vitro andin vivo activity of DL 8280, a new oxazine derivative. Antimicrob. Agents Chemother. 22 (1982) 548–553.
2. Seibert, G., Limbert, M., Klesel, N. Comparison of the antibacterialin vitro andin vivo activity of ofloxacin (HOE 280, DL 8280) and nalidixic acid analogues. Eur. J. Clin. Microbiol. 2 (1983) 548–553.
3. Tanimara, H., Kobayashi, N., Saito, T., Sato, T., Takahashi, H., Huang, W. F., Hikasa, Y.: Excretion into bile, tissue level of gall-bladder and clinical effects of DL 8280 for biliary tract infections. In:Spitzy, K.-H., Karrer, K. (eds.): Proceedings of the 13th International Congress of Chemotherapy, Vienna 1983, part 125, pp. 21–26.
4. Suzuki, K., Nagakubo, I., Bandok, T., Aoki, S., Naide, Y.: Clinical evaluation of DL 8280 in bacterial prostatitis. In:Spitzy, K. H., Karrer, K. (eds.): Proceedings of the 13th International Congress of Chemotherapy, Vienna 1983, part 125, pp. 37–40.
5. Kobayashi, H., Takamura, K.: Clinical effects of DL 8280, a new synthetic antimicrobial agent, on lower respiratory tract infection. In:Spitzy, K. H., Karrer, K. (eds.): Proceedings of the 13th International Congress of Chemotherapy, Vienna 1983, part 125, pp. 45–48.